Detalles de la búsqueda
1.
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Int J Gynecol Cancer
; 33(4): 562-570, 2023 04 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36564099
2.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35358455
3.
Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies.
Br J Cancer
; 116(12): 1505-1512, 2017 Jun 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28463960
4.
Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling.
Cell Chem Biol
; 2024 Mar 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-38537632
5.
The discovery of tetrahydro-beta-carbolines as inhibitors of the kinesin Eg5.
Bioorg Med Chem Lett
; 20(1): 157-60, 2010 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19945875
6.
Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
Cancer Treat Res Commun
; 25: 100260, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33310366
7.
First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
J Clin Oncol
; 38(16): 1824-1835, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32213105
8.
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
Eur J Cancer
; 109: 103-110, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30711772
9.
Inhibition of Cdc7/Dbf4 kinase activity affects specific phosphorylation sites on MCM2 in cancer cells.
J Cell Biochem
; 104(3): 1075-86, 2008 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-18286467
10.
In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.
Mol Cancer Ther
; 13(6): 1468-79, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24723450
11.
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
Cancer Discov
; 3(12): 1404-15, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24065731
Resultados
1 -
11
de 11
1
Próxima >
>>